Compare Inovio Pharmaceuticals Inc (INO) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.16. The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SPUS | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $2.87 | $59.51 |
52-Week Low | $0.66 | $46.28 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
SPUS trades at $59.11, up 0.27% today, with technical indicators showing a bullish trend supported by moving averages. The stock exhibits strong momentum with key indicators favoring upside potential. Recent dividend distributions of $0.03 per share in H1-26 demonstrate shareholder returns, though key valuation metrics remain undisclosed in current data.
The outlook remains positive given technical strength and dividend consistency, though limited fundamental data availability warrants caution. Key risks include market volatility and potential overbought conditions indicated by short-term RSI levels. Investors should monitor upcoming earnings for fundamental validation of current technical optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
